Their latest update was a survey saying that the reversibility trials were proving less successful in their baboon studies after great success in previous studies.  They sent out a survey asking for comments on the importance of reversibility about a month ago.<p>From the email:<p>&gt; A key goal for the first Vasalgel studies, in addition to demonstrating the contraceptive&#x27;s safety and effectiveness, was to establish its reversibility. Vasalgel was reversible after a year in rabbits, but as we&#x27;ve reported, reversibility has so far been elusive in large-animal studies.<p>&gt; We suspect we simply haven&#x27;t found a suitable large-animal model; for example the baboon vas deferens is smaller and more fragile than that of the human. We&#x27;re cautiously optimistic that everything will be much easier in human trials, because the human vas is larger and sturdier. And we&#x27;re hard at work trying some other things too. But in the meantime, the first clinical trial will be designed to include just men who aren&#x27;t counting on reversibility, while we sort out those issues.<p>&gt; Thousands of people would like to be in the first trial, but there are only a few spots. And the researcher will have to pick local men who are the best candidates and want vasectomy anyway. So we&#x27;re trying to keep everybody&#x27;s focus on the ultimate prize: getting Vasalgel to market, with availability to ALL. If trials go well, then the sky&#x27;s the limit: we&#x27;ll seek approvals to bring Vasalgel to market, starting in the U.S., E.U., and Canada... and expanding from there.